Amgen (AMGN) : Traders are bullish on Amgen (AMGN) as it has outperformed the S&P 500 by a wide margin of 5.18% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.52%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.95% in the last 1 week, and is up 7.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Amgen (NASDAQ:AMGN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $173.35 and $172.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $174.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $173.66, notching a gain of 0.57% for the day. The total traded volume was 2,228,857 . The stock had closed at $172.67 on the previous day.
The stock has recorded a 20-day Moving Average of 4.27% and the 50-Day Moving Average is 9.26%. Amgen Inc. is up 14.11% in the last 3-month period. Year-to-Date the stock performance stands at 8.43%.
Amgen (AMGN) : Currently there are 12 street experts covering Amgen (AMGN) stock. The most bullish and bearish price target for the stock is $201 and $157 respectively for the short term. The average price target of all the analysts comes to $184. The estimated standard deviation from the target is $14.3.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.